Preliminary effects of oral uridine on the ocular surface in dry eye patients

Journal of Korean Medical Science

Volumn 24, Issue 4, 2009, Pages 701-707

  Chang, Ki Cheol ^a   Oh, Joo Youn ^a   In, Youn Seok ^a   Kim, Mee Kum ^a   Shin, Ki Cheul ^b   Wee, Won Ryang ^a   Lee, Jin Hak ^a   Park, Myung Gyu ^c  

^a Seoul National University College of Medicine   (South Korea)

^b Konkuk University Hospital   (South Korea)

^c MD Bioalpha   (South Korea)

Author keywords

Cornea; Dry eye syndromes; OSDI; Uridine

Indexed keywords

FLUORESCENT DYE; URIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DOUBLE BLIND PROCEDURE; DRY EYE; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CONJUNCTIVA; CORNEA; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; URIDINE;

EID: 70350716487     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2009.24.4.701     Document Type: Article

References (35)

1. Schein OD, Munoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol 1997; 124: 723-8.
2. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17: 584-9.
3. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-9.
4. Aragona P, Papa V, Micali A, Santocono M, Milazzo G. Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol 2002; 86: 181-4.
5. Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci 2001; 42: 96-100.
6. Fujihara T, Murakami T, Nagano T, Nakamura M, Nakata K. INS365 suppresses loss of corneal epithelial integrity by secretion of mucinlike glycoprotein in a rabbit short-term dry eye model. J Ocul Pharmacol Ther 2002; 18: 363-70.
7. 2 agonist, in patients with mild to moderate dry eye disease. Adv Exp Med Biol 2002; 506 (Pt B): 1251-7.
8. Tauber J, Davitt WF, Bokosky JE, Nichols KK, Yerxa BR, Schaberg AE, LaVange LM, Mills-Wilson MC, Kellerman DJ. Double-blinded, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23: 784-92.
9. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
10. 2 nucleotide receptors in rabbit and human conjunctiva. Exp Eye Res 1998; 67: 341-6.
11. Oh JY, In YS, Kim MK, Ko JH, Lee HJ, Shin KC, Lee SM, Wee WR, Lee JH, Park M. Protective effect of uridine on cornea in a rabbit dry eye model. Invest Ophthalmol Vis Sci 2007; 48: 1102-9.
12. Pitsillides AA, Wilkinson LS, Mehdizadeh S, Bayliss MT, Edwards JC. Uridine diphosphoglucose dehydrogenase activity in normal and rheumatoid synovium: the description of a specialized synovial lining cell. Int J Exp Pathol 1993; 74: 27-34.
13. Magee C, Nurminskaya M, Linsenmayer TF. UDP-glucose pyrophosphorylase: up-regulation in hypertrophic cartilage and role in hyaluronan synthesis. Biochem J 2001; 360: 667-74.
14. Pflugfelder SC, Geerling G, Kinoshita S. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 2007; 5: 163-78.
15. Wilson SE, Stulting RD. Agreement of physician treatment practices with the international task force guidelines for diagnosis and treatment of dry eye disease. Cornea 2007; 26: 284-9.
16. Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O'Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC; Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25: 900-7.
17. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004; 15: 299-304.
18. Norn MS. Lissamine green. Vital staining of cornea and conjunctiva. Acta Ophthalmol (Copenh) 1973; 51: 483-91.
19. Martinez AJ, Mills MB, Jaceldo KB, Tio FO, Aigbivbalu IB, Hilsenbeck SB, Yee RW. Standardization of conjunctival impression cytology. Cornea 1995; 14: 515-22.
20. Clinch TE, Benedetto DA, Felberg NT, Laibson PR. Schirmer's test: a closer look. Arch Ophthalmol 1983; 101: 1383-6.
21. Moses RA, Parkison G, Schuchardt R. A standard large wound of the corneal epithelium in the rabbit. Invest Ophthalmol Vis Sci 1979; 18: 103-6.
22. Van Horn DL, Sendele DD, Seideman S, Buco PJ. Regenerative capacity of the corneal endothelium in rabbit and cat. Invest Ophthalmol Vis Sci 1977; 16: 597-613.
23. Olsen EG, Davanger M. The healing of rabbit corneal endothelium. Acta Ophthalmol (Copenh) 1984; 62: 796-807.
24. 2 receptor agonists stimulate Cl- and fluid secretion. Am J Physiol Cell Physiol 2001; 281: C595-602.
25. Murakami T, Fujihara T, Nakamura M, Nakata K. P2Y(2) receptor stimulation increases tear fluid secretion in rabbits. Curr Eye Res 2000; 21: 782-7.
26. Srinivas SP, Yeh JC, Ong A, Bonanno JA. Ca2+ mobilization in bovine corneal endothelial cells by P2 purinergic receptors. Cur Eye Res 1998; 17: 994-1004.
27. Pediani JD, McGrath JC, Wilson SM. P2Y receptor-mediated Ca2+ signalling in cultured rat aortic smooth muscle cells. Br J Pharmacol 1999; 126: 1660-6.
28. 2 receptor-activated transepithelial anion secretion. Am J Physiol 1999; 276: C777-87.
29. Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005; 10 (Suppl 2): M117-23.
30. Kunzelmann K, Mall M. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2003; 2: 299-309.
31. Girot R, Hamet M, Perignon JL, Guesnu M, Fox RM, Cartier P, Durandy A, Griscelli C. Cellular immune deficiency in two siblings with hereditary orotic aciduria. N Engl J Med 1983; 308: 700-4.
32. Van Groeningen CJ, Peters GJ, Nadal JC, Laurensse E, Pinedo HM. Clinical and pharmacologic study of orally administered uridine. J Natl Cancer Inst 1991; 83: 437-41.
33. Al Safarjalani ON, Zhou XJ, Naguib FN, Shi J, Schinazi RF, el Kouni MH. Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: implications for uridine rescue regimens in chemotherapy. Cancer Chemother Pharmacol 2001; 48: 389-97.
34. Venhoff N, Zilly M, Lebrecht D, Schirmer D, Klinker H, Thoden J, Langmann P, Walker UA. Uridine pharmacokinetics of mitocnol, a sugar cane extract. AIDS 2005; 19: 739-40.
35. Tsubota K, Kaido M, Yagi Y, Fujihara T, Shimmura S. Diseases associated with ocular surface abnormalities: the importance of reflex tearing. Br J Ophthalmol 1999; 83: 89-91.